CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC) today announced two executive
leadership changes highlighting the company's commitment to
developing exceptional leaders. Effective April 4, 2022, Philina
Lee, Ph.D. will be promoted to Chief Commercial Officer,
succeeding Christina Rossi as she
transitions to Chief Operating Officer. With her promotion, Dr. Lee
will become an officer of the company and assume responsibility for
Blueprint's global commercial strategy and U.S. operations.
In an expanded role, Helen Ho,
Ph.D., will become Chief Business Officer, adding Portfolio
Strategy & Program Management to her current responsibilities
for Corporate and Business Development. Dr. Lee and Dr. Ho will
join the company's Executive Team.
"I'm thrilled to announce the elevation of these two talented
and dedicated Blueprint Medicines colleagues," said Jeff Albers, Chief Executive Officer, Blueprint
Medicines. "The work of impacting patient lives takes great people
to be successful and we are intentional about cultivating internal
talent, enabling thoughtful succession planning in support of
Blueprint's continued success. We believe we are poised for
transformational growth over the next 12-18 months. As
Philina and Helen step into these roles, their leadership help will
ensure consistency of approach while bringing diversity of
perspective and experience as we work to achieve our goals."
Dr. Lee joined Blueprint Medicines in August 2014 as Senior Director, New Product
Strategy and Development and subsequently held multiple commercial
roles with responsibility for strategy, operations, patient
services, marketing and the precision medicine field team. During
her tenure, she has been instrumental in building the company's
portfolio from research-stage onwards, laying the groundwork for
the commercial strategy that is driving the successful launches of
AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). Since
January 2021, Dr. Lee has served as
Senior Vice President, Head of Portfolio Strategy and Program
Management, responsible for providing strategic and operational
leadership across the company's portfolio. Previously, Dr. Lee held
product strategy and marketing roles of increasing responsibility
at Algeta, Sanofi and Genzyme. Dr. Lee also serves on the board of
Fusion Pharmaceuticals, as a member of both the Nomination and
Governance committee and Research and Development committee. Dr.
Lee earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology
from the Massachusetts Institute of
Technology.
Dr. Ho joined Blueprint Medicines in April 2018 as Vice President, Corporate
Development, to lead business development, corporate strategy, new
product planning and alliance management, and was promoted to
Senior Vice President in January
2021. During her tenure, she has played a central role in
establishing and operating successful strategic partnerships with
Roche, Ipsen, CStone Pharmaceuticals, and Zai Lab, as well as the acquisition of Lengo
Therapeutics. Prior to joining Blueprint Medicines, Dr. Ho served
in corporate development roles at TCR2 Therapeutics and
Agios Pharmaceuticals and as a management consultant at LEK
Consulting. Dr. Ho earned a B.S. in Biochemistry from University of California, Los Angeles, and a Ph.D.
in Cell Biology from Yale
University.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities,
to rapidly and reproducibly translate science into a broad pipeline
of precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans, strategies, timelines and expectations for
Blueprint Medicines' current or future approved drugs and drug
candidates, including timelines for marketing applications and
approvals, the initiation of clinical trials or the results of
ongoing and planned clinical trials; plans to expand Blueprint
Medicines' scientific platform; Blueprint Medicines' plans,
strategies and timelines to nominate development candidates; plans
and timelines for additional marketing applications for avapritinib
and pralsetinib and, if approved, commercializing avapritinib and
pralsetinib in additional geographies or for additional
indications; the potential benefits of any of Blueprint Medicines'
current or future approved drugs or drug candidates in treating
patients; the potential benefits of Blueprint Medicines'
collaborations; preliminary selected financial results; Blueprint
Medicines' strategy, goals, potential growth and related timelines,
and anticipated financial performance, milestones, business plans
and focus; and the potential benefits from Blueprint Medicines'
leadership development and succession planning. The words "aim,"
"may," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the impact of the
COVID-19 pandemic to Blueprint Medicines' business, operations,
strategy, goals and anticipated milestones, including Blueprint
Medicines' ongoing and planned research and discovery activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Blueprint Medicines'
ability and plans in continuing to establish and expand a
commercial infrastructure, and successfully launching, marketing
and selling current or future approved products; Blueprint
Medicines' ability to successfully expand the approved indications
for AYVAKIT/AYVAKYT and GAVRETO or obtain marketing approval for
AYVAKIT/AYVAKYT in additional geographies in the future; the delay
of any current or planned clinical trials or the development of
Blueprint Medicines' current or future drug candidates; Blueprint
Medicines' advancement of multiple early-stage efforts; Blueprint
Medicines' ability to successfully demonstrate the safety and
efficacy of its drug candidates and gain approval of its drug
candidates on a timely basis, if at all; the timing and results of
preclinical and clinical studies for Blueprint Medicines' drug
candidates, which may not support further development of such drug
candidates or may impact the timing of data publications or
regulatory submissions; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials;
Blueprint Medicines' ability to obtain, maintain and enforce patent
and other intellectual property protection for AYVAKIT/AYVAKYT,
GAVRETO or any drug candidates it is developing; Blueprint
Medicines' ability to develop and commercialize companion
diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current
and future drug candidates; Blueprint Medicines' ability to
successfully expand its operations and scientific platform and the
costs thereof; the success of Blueprint Medicines' current and
future collaborations, partnerships or licensing arrangements;
and Blueprint Medicines' ability to realize the anticipated
benefits of its succession planning and leadership development and
transitions. These and other risks and uncertainties are described
in greater detail in the section entitled "Risk Factors" in
Blueprint Medicines' filings with the Securities and Exchange
Commission (SEC), including Blueprint Medicines' most recent Annual
Report on Form 10-K, as supplemented by its most recent Quarterly
Report on Form 10-Q and any other filings that Blueprint Medicines
has made or may make with the SEC in the future. Any
forward-looking statements contained in this press release
represent Blueprint Medicines' views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Except as required by law, Blueprint Medicines
explicitly disclaims any obligation to update any forward-looking
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-elevates-two-talented-leaders-to-its-executive-team-301464448.html
SOURCE Blueprint Medicines Corporation